Cellgen Diagnostics and Genomic Testing Cooperative Partner

Cellgen Diagnostics and Genomic Testing Cooperative Partner

CELLGEN DIAGNOSTICS AND GENOMIC TESTING COOPERATIVE PARTNER TO ESTABLISH A NEW STANDARD IN CO-DEVELOPMENT OF COMPANION DIAGNOSTICS FOR CANCER THERAPIES Alliance will enable a faster and more rigorous approach to biomarker discovery and companion diagnostic co-development  Irvine, CA—April 3, 2019—Cellgen Diagnostics, a leading precision diagnostics company, and Genomic Testing Cooperative (GTC), a pioneer in molecular testing, today announced a strategic collaboration to help accelerate global development of companion tests for various oncology therapeutics. The collaboration, between GTC’s Next Generation Sequencing (NGS), artificial intelligence (AI) based biomarker discovery service and Cellgen’s integrated companion diagnostics platform will provide the pharmaceutical industry a seamless integration of biomarker discovery, validation and development of in […]

Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Order GTC Hematology Expression/Fusion Profile   The GTC Hematology Expression/Fusion test provides actionable information for: 1) Determining Fusion and classification (Ph-Positive or Ph-Like) Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with genomic alterations dominated by structural chromosomal abnormalities, particularly translocations. Most of the reported chromosomal translocations in ALL lead to the expression of fusion RNAs and proteins that frequently upregulate expression of oncoproteins or the expression of more potent oncoprotein. Philadelphia chromosome-positive (Ph1) ALL is one of the subtypes of ALL that is characterized by t(9;22)(q34;q11) and produces constitutively active BCR-ABL1 fusion oncoprotein. Ph-positive ALL is common in adults and detected in almost 25% of patients but rare in […]

23rd Annual International Congress on Hematologic Malignancies 2019

23rd Annual International Congress on Hematologic Malignancies 2019

23rd Annual International Congress on Hematologic Malignancies 2019: Focus on Leukemias, Lymphomas and Myeloma   The annual International Congress on Hematologic Malignancies is dedicated to providing clinicians access to emerging data in treating hematologic malignancies. Providing practical tools to optimize therapy and personalize care. Our Chief Medical Officer Dr. Maher Albitar will be presenting Beyond Genomics: Integrating Molecular Medicine in Our Practice on Friday March 1st, 8:40am. Few words about the Congress Now in its 23rd year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies the practical tools to translate emerging data into the best therapy for patients with these tumors, […]

Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma (DLBCL)

Order GTC Hematology Expression/Fusion Profile GTC Hematology Expression/Fusion Profiling provides highly informative and actionable data for patients with DLBCL as follows: 1) B-cell Markers: This assay provides data on the expression of markers specific to B-cell. It will report the levels of expression of B-cell markers, including CD19, CD79A, CD79B, PAX5, CD22, and others. The levels of CD274 (PD-L1) will also be determined and reported. After confirming that the case is B-cell neoplasm, multiple algorithms and deep learning are used to determine the following: 2) Cell of Origin (COO): Diffuse large B-cell lymphomas (DLBCLs) are clinically heterogeneous group and outcome varies significantly between patients irrespective of treatment protocol. However, determining […]

Sarcoma Diagnosis and Classification

Sarcoma Diagnosis and Classification

Order GTC Solid Tumor Expression/Fusion Profile Sarcoma Diagnosis and Classification. The GTC Solid Tumor Expression/Fusion Profiling provides highly informative and actionable data for patients with sarcoma. Sarcomas are heterogeneous group of cancer that arises in the connective tissue. Diagnosis and subclassification of sarcoma can be very difficult due to overlapping in histological and immunohistological features. Determining the molecular abnormalities, especially fusion genes and chromosomal translocations in a specific sarcoma can be very helpful in diagnosis, subclassification and determining therapy. Sarcoma is a rare cancer type, but it is relatively more common in pediatric patients. In general, the presence of a specific translocation in one sarcoma type does not occur in […]

INTERVIEW: Introduction to Genomic Testing Cooperative by Dr. Maher Albitar

INTERVIEW: Introduction to Genomic Testing Cooperative by Dr. Maher Albitar

A quick interview from Genomic Testing Cooperative founder, CEO/CMO, Dr. Albitar, introducing Genomic Testing Cooperative answering questions about it… Get all the  answers by watching the following video:  What is a precision diagnosis? What makes GTC different? What is the co-op model? How does GTC deliver value in genomic testing? How does GTC use artificial intelligence? How does GTC disrupt the genomic testing market? What will be reported from GTC testing? How do you support community-based labs? How does GTC model contribute to companion testing?

Looking for an answer quickly from your NGS provider?

Looking for an answer quickly from your NGS provider?

Time Matters on Health Tests When dealing with cancer, clinicians and patients need to know the results of molecular testing as soon as possible.  Are you waiting 21-28 days to receive your NGS results? Genomic Testing Cooperative (GTC) is using disruptive technology and will report results within 7 days of receiving the sample.  GTC tests all coding sequence of 434 genes for solid tumors and 177 genes for hematology and provides a comprehensive report within 7 days from receiving a sample. Despite this extensive testing and comprehensive reporting, GTC manages to offer these panels at an affordable price.  For more information on these two tests and others, check out our […]

CSI Laboratory is the first to offer 177 gene liquid biopsy for hematology

CSI Laboratory is the first to offer 177 gene liquid biopsy for hematology

-a step forward to precision in cancer diagnostics- CSI LABORATORIES ADVANCES BY PARTNERING WITH DR. MAHER ALBITAR OF GENOMICS TESTING COOPERATIVE (GTC)  Membership in the Co-op also makes CSI Laboratory the first to offer 177 gene liquid biopsy for hematology   ALPHARETTA –   CSI Laboratories, nationally renowned for its quality cancer diagnostics, goes a step forward to precision cancer diagnostics. Today announces its partnership with Genomic Testing Cooperative (GTC) in order to provide a new level of Next Generation Sequencing to the market.  This partnership combines the gold standard in quality cancer diagnostics with advanced genomics technology – giving pathologists and oncologists access to the most comprehensive and detailed cancer data. This information also […]

Acute Lymphoblastic Leukemia | Just published: A consensus of North American experts

Acute Lymphoblastic Leukemia | Just published: A consensus of North American experts

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts The vast majority of adults with acute lymphoblastic leukemia (ALL) achieve remission with standard chemotherapy regimens, but many of these patients ultimately relapse and die from leukemia. In these patients, relapse occurs despite achievement of morphologic remission (ie, bone marrow blasts <5%), suggesting that low levels of measurable residual disease (MRD), also called “minimal residual disease,” persist in the remission bone marrow (Figure 1). Compared with morphologic assessment alone, sensitive methods of MRD quantification can better estimate the reduction in posttreatment disease burden and provide information about the leukemia biology and treatment response of individual patients. Posttreatment MRD status […]

Eltrombopag Improves Hematopoiesis

Eltrombopag Improves Hematopoiesis

Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome(MDS) Program: Oral and Poster Abstracts | Saturday, December 1, 2018: 4:00 PM Session: 637. Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics I Eltrombopag (EPAG), a thrombopoietin receptor agonist, has been shown to improve hematopoiesis in patients with aplastic anemia (AA), but in MDS patients the effect of thrombopoietin mimetics in bone marrow function is still unclear. In this phase-2 dose escalation study, we investigated the safety and effectiveness of EPAG treatment in low to intermediate-2 risk MDS patients (NCT 00961064). Thirty patients were enrolled from March […]